Results 31 to 40 of about 54,075 (219)

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents

Frontiers in Oncology, 2022
Trastuzumab is a standard molecular targeted therapy for human epidermal growth factor receptor 2(HER2) -positive breast cancer, which can significantly improve the survival of patients with this molecular subtype of breast cancer.
Zhen-hao Wang, Zhen-hao Wang, Zhuo-qun Zheng, Shi−cheng Jia, Shu-ni Liu, Xiao-fen Xiao, Xiao-fen Xiao, Guan-yuan Chen, Guan-yuan Chen, Wei-quan Liang, Wei-quan Liang, Xiao-feng Lu, Xiao-feng Lu   +12 more
doaj   +1 more source

miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer

Cell Death and Disease, 2021
Trastuzumab resistance negatively influences the clinical efficacy of the therapy for human epidermal growth factor receptor 2 (HER2) positive gastric cancer (GC), and the underlying mechanisms remain elusive.
Jing Guo, Xuxian Zhong, Qinglin Tan, Shengnan Yang, Jiaqi Liao, Jinke Zhuge, Ziyang Hong, Qiong Deng, Qiang Zuo   +8 more
doaj   +1 more source

circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer

Molecular Cancer, 2022
Background Approximate 25% HER2-positive (HER2+) breast cancer (BC) patients treated with trastuzumab recurred rapidly. However, the mechanisms underlying trastuzumab resistance remained largely unclear.
Yun Ling, Gehao Liang, Qun Lin, Xiaolin Fang, Qing Luo, Yinghuan Cen, Maryam Mehrpour, Ahmed Hamai, Zihao Liu, Yu Shi, Juanmei Li, Wanyi Lin, Shijie Jia, Wenqian Yang, Qiang Liu, Erwei Song, Jun Li, Chang Gong   +17 more
doaj   +1 more source

Human Blood Serum Inhibits Ductal Carcinoma Cells BT474 Growth and Modulates Effect of HER2 Inhibition

Biomedicines, 2022
Trastuzumab, a HER2-targeted antibody, is widely used for targeted therapy of HER2-positive breast cancer (BC) patients; yet, not all of them respond to this treatment.
Dmitrii Kamashev, Nina Shaban, Maria Suntsova, Mikhail Raevskiy, Victor Efimov, Aleksey Moisseev, Maxim Sorokin, Anton Buzdin   +7 more
doaj   +1 more source

Blood‐based proteomic profiling reveals context‐dependent changes in BCL2‐associated signaling during taxane therapy in breast cancer patients

FEBS Open Bio, EarlyView.
Chemotherapy side effects significantly impact cancer survivors' quality of life. Using protein levels in blood samples from breast cancer patients before and after 12 weeks of taxane treatment, we detected treatment‐dependent changes in calcium signaling and aging pathways associated with cancer recurrence.
Saira Munshani, Eiman Y. Ibrahim, Rozalyn L. Rodwin, Leah M. Ferrucci, Kim Blenman, Maryam Lustberg, Barbara E. Ehrlich   +6 more
wiley   +1 more source

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study

Pharmaceuticals, 2021
This study aimed to compare drug costs and healthcare costs of a 1 year adjuvant course with intravenous biosimilar trastuzumab vs. subcutaneous reference trastuzumab in HER2-positive breast cancer from the Belgian hospital perspective. Our simulation is
Steven Simoens, Arnold G. Vulto, Pieter Dylst   +2 more
doaj   +1 more source

Deciphering the Role of Cancer Stem Cells in Breast Cancer Brain Colonization Using a Novel Patient‐Derived Model

Advanced Healthcare Materials, EarlyView.
This study shows that stem‐like cells isolated from breast cancer brain metastases drive the spread and growth of tumors in the brain. Among them, a highly adhesive subgroup initiates metastasis and resists many drugs. By closely reflecting patient tumors, these models help identify new targets and improve the development of effective treatments ...
Stefania Faletti, Cristina Richichi, Daniela Osti, Elena Ceccacci, Giovanni Bertalot, Camilla Cerutti, Giuseppina Giardina, Adriana Marinaro, Brunella Costanza, Valentina Gambino, Elena Zaccheroni, Daniela Tosoni, Maria G. Filippone, Marcello Del Corvo, Yinxiu Zhan, Teresa Gravina, Davide Corà, Monica Patanè, Bianca Pollo, Maria Giovanna Jodice, Salvatore Pece, Babette B. Weksler, Ignacio A. Romero, Pierre‐Olivier Couraud, Elisabetta Munzone, Massimiliano Del Bene, Francesco DiMeco, Giuliana Pelicci   +27 more
wiley   +1 more source

Plant‐Produced Viral Nanoparticles Decorated with Nanobodies Against HER2 Improve Retention and Recruitment of Immune Cells in Solid Tumors

Advanced Healthcare Materials, EarlyView.
Potato virus X is a filamentous RNA plant virus that can be engineered into a molecular tool for cancer therapy. We produced genetically‐encoded virus‐derived nanoparticles decorated with nanobodies targeting cancer cell receptors, epidermal growth factor receptor (EGFR) and human epidermal growth factor 2 (HER2).
Enrique Lozano‐Sanchez, Miguel A. Moreno‐Gonzalez, Fernando Merwaiss, Nicole F. Steinmetz, José‐Antonio Daròs   +4 more
wiley   +1 more source

Efficacy and safety of small-molecule TKIs in neoadjuvant treatment of HER2-positive breast cancer: a systematic review and network meta-analysis

BMC Cancer
Objective This study aimed to evaluate the efficacy and safety of small-molecule TKIs in neoadjuvant treatment of HER2-positive breast cancer using a network meta-analysis approach.
Chaoyang Wang, Dong Xiao, Chao Zhai
doaj   +1 more source

Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT

Health Technology Assessment, 2020
Background: The addition of adjuvant trastuzumab to chemotherapy has significantly improved outcomes for people with human epidermal growth factor receptor 2 (HER2)-positive, early, potentially curable breast cancer. Twelve months’ trastuzumab, tested in
Helena Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi, Karen McAdam, Luke Hughes-Davies, Daniel Rea, Donna Howe, Kerry Raynes, Helen B Higgins, Maggie Wilcox, Chris Plummer, Betania Mahler-Araujo, Elena Provenzano, Anita Chhabra, Sophie Gasson, Claire Balmer, Jean E Abraham, Carlos Caldas, Peter Hall, Bethany Shinkins, Christopher McCabe, Claire Hulme, David Miles, Andrew M Wardley, David A Cameron, Janet A Dunn   +26 more
doaj   +1 more source